Recent News

• 04.23.2025 - MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
• 04.23.2025 - MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
• 04.22.2025 - MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
• 04.22.2025 - MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
• 04.15.2025 - MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control
• 04.15.2025 - MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control
• 03.20.2025 - MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
• 03.20.2025 - MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Recent Filings

• 04.22.2025 - 8-K Current report
• 04.22.2025 - EX-99.1 EX-99.1
• 04.15.2025 - 8-K Current report
• 04.15.2025 - EX-99.1 EX-99.1
• 04.15.2025 - EX-99.1 EX-99.1
• 04.15.2025 - 8-K Current report
• 04.04.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 04.03.2025 - EFFECT Notice of Effectiveness
• 03.27.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.27.2025 - POS AM Post-Effective amendments for registration statement